Aduhelm (Drug)
January 6, 2023
[ad_1] The drug Leqembi may slightly slow cognitive decline in the early stages of the disease, but it comes with some safety risks. However, data suggests it holds more promise than the small number of other treatments available. [ad_2] Source link
December 29, 2022
[ad_1] The report said the FDA’s approval process for Aduhelm was “riddled with irregularities” and criticized Biogen for setting an “unjustifiably high price.” [ad_2] Source link
September 27, 2022
[ad_1] Biogen and Eisai reported the results of a large, late-stage clinical trial of lecanemab, a drug they are developing. [ad_2] Source link
